OKYO Pharma Gains Buy Ratings After FDA Endorses Urcosimod Trial Design
OKYO Pharma maintained Buy ratings from Lucid Capital, H.C. Wainwright and B. Riley Securities after a Type C meeting with the US Food and Drug Administration supported its urcosimod trial design. FDA feedback validated the company’s Phase II neuropathic corneal pain study design, clearing a key regulatory step.
1. Analyst Ratings
OKYO Pharma received Buy ratings from Lucid Capital, H.C. Wainwright and B. Riley Securities following a positive regulatory meeting. Analysts cited the strong trial design for urcosimod in treating neuropathic corneal pain as the primary reason for their upgraded outlook.
2. FDA Type C Meeting Outcome
During the Type C meeting, FDA reviewers provided supportive feedback on the company’s proposed Phase II study of urcosimod, validating endpoints and patient selection criteria. This endorsement removes a significant uncertainty ahead of trial initiation and positions OKYO Pharma to proceed toward first patient dosing.